Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok2. fázis

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension

A legfontosabb adatok

Ki végzi
Brigham and Women's Hospital
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
75 fő, tervezett
Kezdés
2027. jan. 1.
Várható befejezés
2030. máj. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Tirzepatide
  • Placebo
  • Acetazolamide
A regiszteradat frissítve
2026. november 18.

Ki vehet részt

Életkor
18 év – 55 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial:; (i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure >25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause of secondary intracranial hypertension (e.g., tumor, hydrocephalus, venous sinus thrombosis)
  • BMI ≥25
  • Able to provide informed consent

Ki nem vehet részt

  • Treatment for IIH for more than 30 days in the prior year with any agent (acetazolamide, topiramate, furosemide, zonisamide, GLP-1 or dual GLP-1/GIP agonist); if on acetazolamide in the prior month, dose must not have exceeded 1 g/day
  • Prior intracranial shunting, venous sinus stenting, or optic nerve sheath fenestration
  • Bariatric surgery within the past year
  • Major CT/MRI abnormalities suggesting secondary intracranial hypertension or alternate diagnosis (e.g., hydrocephalus, Chiari malformation, dural AV fistula, venous sinus thrombus, retrobulbar optic nerve enhancement suggesting optic neuritis)
  • History of optic neuritis, multiple sclerosis, MOG antibody disease, neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, or seropositivity for MOG or aquaporin-4 antibodies
  • Exposure for >7 days within 2 months of symptom onset to an oral drug, substance, or disorder potentially affecting ICP (e.g., vitamin A derivatives, tetracyclines, growth hormone, lithium, corticosteroids)
  • Comorbid condition requiring diuretics, systemic steroids, or other ICP-lowering agents including topiramate or zonisamide (nasal, inhaled, or topical steroids permitted)
  • Other disorders causing visual loss except refractive error and amblyopia
  • Lab abnormalities or conditions contraindicating GLP-1/GIP agonist use, including type 1 diabetes, diabetic retinopathy, diabetes managed with insulin or a secretagogue, current hypoglycemia, gallbladder disease, pancreatitis, or personal or family history of medullary thyroid cancer
  • Lab abnormalities or conditions contraindicating acetazolamide (severe anemia, leukopenia, thrombocytopenia, renal failure, hepatic disease, calcium phosphate or calcium oxalate nephrolithiasis)
  • IIH relapse at prescreen/screen
  • New cranial nerve dysfunction other than papilledema and sixth nerve palsy
  • CSF leak confirmed by beta-2 transferrin within 1 month of enrollment
  • Media opacity precluding adequate OCT signal strength and Frisén grading
  • Unreliable automated perimetry (≥30% fixation losses, ≥20% false positives or negatives) at screening
  • PMD of -15 dB or worse on reliable perimetry
  • Intraocular pressure currently >28 mmHg or >30 mmHg at any time in the past
  • Refractive error greater than ±8.00 sphere or ±3.00 cylinder in either eye if associated with anatomic abnormalities that could cause visual loss
  • Optic disc drusen on fundus examination or OCT
  • Pregnancy, or unwillingness of participants of childbearing potential to use two methods of birth control, including a non-pharmacologic barrier method, during the study and for 1 month after
  • Breastfeeding, unless willing to stop by the baseline visit

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 55 év között vagy?

Helyszínek itt: Egyesült Államok

  • Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: Eleonore KugenerToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are:

A teljes eredeti leírásKevesebb

* Does tirzepatide lower the mean daily acetazolamide dose at 12 months? * Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension?

Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache.

In addition to receiving treatment with acetazolamide, participants will:

* Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation. * Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing. * During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment. * Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.

A vizsgálat 2 csoportja

  • Acetazolamide + TirzepatideA vizsgált kezelés

    Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling.

    Kezelés: Tirzepatide és Acetazolamide

  • Acetazolamide + PlaceboPlacebo, összehasonlításként

    Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling.

    Kezelés: Placebo és Acetazolamide

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide
Kérdések a feltételekről
Forrás: NCT07946315: ki vehet részt
A regiszteradat frissítve
2026. november 18.